Darolutamide
- Generic Name
- Darolutamide
- Brand Names
- Nubeqa
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN6O2
- CAS Number
- 1297538-32-9
- Unique Ingredient Identifier
- X05U0N2RCO
- Background
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patient...
- Indication
Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
- Associated Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- -
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 54
- Registration Number
- NCT06190899
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸Hospital Clinic Barcelona, Barcelona, Spain
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 75
- Registration Number
- NCT06173362
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT06169124
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1800
- Registration Number
- NCT06120491
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT05999968
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Comunidad De, Spain
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇩🇪Studienpraxis Urologie, Nürtingen, Baden-Württemberg, Germany
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT05938270
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- GenesisCare USA
- Registration Number
- NCT05771896
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 245
- Registration Number
- NCT05762536
- Locations
- 🇳🇱
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 56
- Registration Number
- NCT05694819
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.